TGFB2 and non-small cell lung carcinoma: For instance, TGFB2 induced epithelial-mesenchymal transition and activated the NF-κB pathway to contribute to osimertinib resistance in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer [27].